NOVARTIS N - Dusseldorf Stock Exchang (NOT DU) stock market data APIs
€103.0289
1.14(1.1%)
as of July 4, 2025
Try our APIs with
free plan!
NOVARTIS N - Dusseldorf Stock Exchang Financial Data Overview
Price chart is built with
Anychart
There is no Profile data available for NOT.DU.
Prev. Close
103.0289
Open
104.1703
High
104.3978
Low
104.1703
52 wk Range
71.5574-105.58
Market Cap
160 075 M
Dividends (Yield)
0.0487
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get NOVARTIS N - Dusseldorf Stock Exchang data using free add-ons & libraries
Get NOVARTIS N - Dusseldorf Stock Exchang Fundamental Data
NOVARTIS N - Dusseldorf Stock Exchang Fundamental data includes:
- Net Revenue:
- EBITDA:
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
Get NOVARTIS N - Dusseldorf Stock Exchang End-of-day data
EOD Historical Data package for
$
19.99
/mo.
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NOVARTIS N - Dusseldorf Stock Exchang News
New
Switzerland seeks trade deal with Trump without getting into EU bind
By Dave Graham ZURICH (Reuters) -Switzerland is exploring what concessions it can make to secure a deal with Washington on trade, but it must tread carefully to protect its interests with key trading...
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study
Novartis NVS announced that a late-stage study of its interleukin-17A inhibitor, Cosentyx (secukinumab), has failed to meet the primary endpoint of sustained remission at week 52 for a new indication ...
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
Regeneron Pharmaceuticals, Inc. REGN obtained FDA approval for linvoseltamab-gcpt for the treatment of relapsed or refractory (R/R) multiple myeloma (MM). The regulatory body granted accelerated appr...
Business and Investment Opportunities in Nuclear Medicine 2025-2030: North America Leads, Asia-Pacific Races
Company Logo Nuclear Medicine MarketNuclear Medicine Market Dublin, July 03, 2025 (GLOBE NEWSWIRE) -- The "Nuclear Medicine Market Size, Share & Trends Analysis Report by Product (Diagnostics, Thera...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
